God is our Guide  Number 1 site for helping reverse diseases on Planet Earth



Coconut oil Benefits

B-12 deficiency

Alkaline Foods

Oils for health

Cancer Mycoplasma

Takayasu arteritis

Temporal arteritis

Polymyalgia Rheumatica

Behcet Disease

Autoimmune autism

Low fat diet consequences

Subcutaneous IVIg

Acromegaly page   





  Prognosis CIDP & Autoimmune diseases  CIDPUSA Foundation

   alternatives treatment of autoimmune disease read our e-book 

Our five year follow up study showed that the long term prognosis of Japanese CIDP patients was generally favourable; 87% of the 38 patients were able to walk five years later, and 26% experienced complete remission lasting for more than two years without treatment. However, 39% of the patients still required immune treatments, and 13% had severe disability. Further follow up for six to 15 years showed similar results, suggesting that the prognosis of CIDP may be determined by the course and response to treatment in the first five years.


CIDP patients with complete remission more often had subacute onset, symmetrical symptoms, a good response to initial treatment with corticosteroids, and nerve conduction abnormalities predominant in the distal nerve terminals than the other patients. These factors can be predictors of long term outcome. Mode of onset or progression time from onset to nadir is an important prognostic factor. All 10 patients with complete remission had a subacute onset. The possibility that these patients had acute inflammatory demyelinating polyneuropathy (Guillain–Barré syndrome) could be eliminated because they definitely had a progression time of over two months. Moreover, nine of the 10 patients were obviously responsive to corticosteroids, and this is not the case for Guillain–Barré syndrome.